Merck acquisition would put emboldened regulators to the test

For the participants of the two-day regulatory workshop on strengthening antitrust enforcement in the pharmaceutical industry, the message could not have been clearer: the times when mega-mergers could sail through without much scrutiny are over.

Then, almost as if presenting a test case to antitrust officials, the Wall Street Journal reported on this New Jersey-based firm two days later note & Co. planned to purchase Seattle Area-Biotech blessings which is now worth just over $30 billion. The report noted that there may be other interested parties and that a deal could be difficult to push through “given the increased risk of a regulatory challenge.” Merck acquisition would put emboldened regulators to the test

Luke Plunkett is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button